Nicox SA
PAR:COX
Nicox SA
PAR:COX
Price:
0.579
EUR
-0.52%
Market Cap:
€28.9m
Relative Value
There is not enough data to reliably calculate the relative value of COX.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
COX
Relative Value
Base Case
Not Available
Multiples Across Competitors
COX Competitors Multiples
Nicox SA Competitors
Nicox SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Nicox SA
PAR:COX
|
28.8m EUR | 8.8 | -1 | -1.8 | -0.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
412.2B USD | 6.7 | 98.6 | 16.1 | 22.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.2B USD | 5.5 | 26 | 14.9 | 14.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
183.4B USD | 6.2 | 21.4 | 13.3 | 16.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.8B USD | 10 | 30.4 | 22.9 | 24 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.3B USD | 5.7 | 18.1 | 13.5 | 15.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.1B AUD | 3.2 | 35.1 | 11.6 | 14.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.9B EUR | 11.3 | 36.4 | 39.7 | 40.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
